SCHEMBL1011802

SCHEMBL1011802

CC(C)(C)OC(=O)N1C[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](C(=O)O)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.41
PDE4B Q07343 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 1/20 0.36
TACR1 P25103 2/20 0.33
RECQL P46063 1/20 0.33
NAMPT P43490 1/20 0.33
GAA P10253 1/20 0.33
THRB P10828 1/20 0.33
RORC P51449 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
TOP2A P11388 1/20 0.32
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31153812 0.90 RECQL (0.40) SMN1; SMN2USP2RECQLGAATHRB
SCHEMBL1015272 0.88 PDE4B (0.44) NR1H2PDE4BSMN1; SMN2USP2TACR1
SCHEMBL14805515 0.85 NR1H2 (0.38) NR1H2PDE4BSMN1; SMN2USP2TACR1
SCHEMBL16909934 0.85 NR1H2 (0.38) NR1H2PDE4BSMN1; SMN2USP2TACR1
SCHEMBL16909933 0.85 NR1H2 (0.38) NR1H2PDE4BSMN1; SMN2USP2TACR1
SCHEMBL30455847 0.85 NR1H2 (0.43) NR1H2PDE4BSMN1; SMN2USP2RECQL
SCHEMBL16096256 0.84 NR1H2 (0.49) NR1H2PDE4BSMN1; SMN2USP2RECQL
SCHEMBL1018269 0.84 NR1H2 (0.49) NR1H2PDE4BSMN1; SMN2USP2RECQL
SCHEMBL17841916 0.84 NR1H2 (0.43) NR1H2PDE4BSMN1; SMN2USP2RECQL
SCHEMBL2929277 0.84 NR1H2 (0.49) NR1H2PDE4BSMN1; SMN2USP2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2272858-A2 HCV inhibitors comprising beta amino acids and their uses Novartis AG (CH) 2011-01-12 EP disclosed
EP-2007787-A2 HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES Novartis AG (CH) 2008-12-31 EP disclosed
US-20080045530-A1 Organic Compounds and Their Uses BRANDL TRIXI 2008-02-21 US disclosed
US-20080045530-A1 Organic Compounds and Their Uses BRANDL TRIXI 2008-02-21 US disclosed
WO-2007121124-A2 HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES NOVARTIS AG (CH) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045530-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 NR1H2 531/4885PDE4B 3578/4885SMN1; SMN2 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.